Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study.
adenosine
hypoxia
immune checkpoint inhibitor
immunosuppression
ipilimumab
multiplex immunohistochemistry
radiotherapy
spatial statistics
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Dec 2020
13 Dec 2020
Historique:
received:
29
11
2020
revised:
10
12
2020
accepted:
11
12
2020
entrez:
16
12
2020
pubmed:
17
12
2020
medline:
17
12
2020
Statut:
epublish
Résumé
Following the introduction of immune checkpoint inhibitors, a substantial prolongation of the overall survival has been achieved for many patients with multiple brain metastases from melanoma. However, heterogeneity between individual tumor responses is incompletely understood. In order to determine the impact of the individual tumor phenotype on the prognosis of melanoma patients, we examined surgical sections from 33 patients who were treated with radiotherapy (whole-brain radiotherapy, WBRT, stereotactic radiotherapy, STX, or both) and Ipilimumab. We analyzed multiplex staining of the hypoxia marker GLUT-1, the adenosine (ADO)-associated enzymes CD73 and CD39, and CD8, a marker of cytotoxic T lymphocytes (CTL) on a single-cell basis using QuPath. Additionally, the MOSAIC interaction analysis algorithm was used to explore the hypothesis that CTL systematically avoid GLUT-1
Identifiants
pubmed: 33322215
pii: cancers12123753
doi: 10.3390/cancers12123753
pmc: PMC7763902
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Varian Medical Systems
ID : Role of adenosine mediated immunosuppression for radiotherapy of melanoma
Références
Front Immunol. 2018 Jul 16;9:1591
pubmed: 30061885
Curr Opin Pharmacol. 2016 Aug;29:7-16
pubmed: 27209048
Oncotarget. 2018 Jun 1;9(42):26659-26669
pubmed: 29928476
J Clin Invest. 2002 Oct;110(7):993-1002
pubmed: 12370277
BMC Cancer. 2012 Sep 04;12:388
pubmed: 22947392
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Pharmacol Res Perspect. 2019 Jul 22;7(4):e00506
pubmed: 31367385
Cancer Metastasis Rev. 2007 Jun;26(2):225-39
pubmed: 17440684
Oncoimmunology. 2015 Aug 12;5(2):e1071007
pubmed: 27057436
Radiother Oncol. 1997 Aug;44(2):163-9
pubmed: 9288845
Oncoimmunology. 2019 Apr 3;8(7):1593806
pubmed: 31143514
Oncotarget. 2015 Oct 20;6(32):32748-60
pubmed: 26293674
Immunotherapy. 2019 Mar;11(4):297-309
pubmed: 30606066
Antioxid Redox Signal. 2007 Aug;9(8):1221-35
pubmed: 17536958
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Melanoma Res. 1997 Oct;7(5):400-6
pubmed: 9429223
Cancer Immunol Res. 2015 Mar;3(3):254-65
pubmed: 25403716
Strahlenther Onkol. 2018 Dec;194(12):1144-1151
pubmed: 30298365
Nature. 1968 Dec 28;220(5174):1352-4
pubmed: 4302696
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Int J Radiat Biol. 2009 Nov;85(11):981-8
pubmed: 19895275
Cancer Res. 2002 Dec 1;62(23):7066-74
pubmed: 12460928
Oncotarget. 2015 Sep 22;6(28):25602-18
pubmed: 26329660
Immunity. 2015 Sep 15;43(3):435-49
pubmed: 26377897
Nat Cancer. 2020 Feb;1(2):210-221
pubmed: 32110781
JCI Insight. 2019 Mar 7;4(5):
pubmed: 30721155
Cancer Res. 2008 Jun 15;68(12):4719-26
pubmed: 18559518
J Histochem Cytochem. 2007 Jun;55(6):545-54
pubmed: 17242468
Sci Transl Med. 2015 Mar 4;7(277):277ra30
pubmed: 25739764
Cancer Res. 1986 Jun;46(6):3011-7
pubmed: 3486040
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Adv Exp Med Biol. 2016;876:177-183
pubmed: 26782210
Front Immunol. 2018 Apr 18;9:813
pubmed: 29720980
Int J Cancer. 2011 May 1;128(9):2085-95
pubmed: 20607826
PLoS One. 2012;7(3):e33571
pubmed: 22442699
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
J Clin Oncol. 2019 Jan 1;37(1):52-60
pubmed: 30407895
Cancer. 2011 Apr 15;117(8):1687-96
pubmed: 20960525
BMC Cancer. 2018 Apr 27;18(1):490
pubmed: 29703161
Nat Rev Cancer. 2017 Dec;17(12):709-724
pubmed: 29059149
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13003-8
pubmed: 18723683
Pathol Oncol Res. 2019 Jan;25(1):361-368
pubmed: 29128957
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Br J Cancer. 2016 Nov 22;115(11):1351-1358
pubmed: 27802455
Tumour Biol. 2019 Apr;42(4):1010428319837138
pubmed: 30957676
Eur J Surg Oncol. 2017 Mar;43(3):604-611
pubmed: 27769635
Br J Cancer. 2010 Apr 13;102(8):1213-8
pubmed: 20372154
J Neurooncol. 2018 Jun;138(2):299-306
pubmed: 29453679
Pigment Cell Melanoma Res. 2015 Sep;28(5):490-500
pubmed: 25818762
Cancers (Basel). 2020 Nov 20;12(11):
pubmed: 33233603
Clin Cancer Res. 2019 Sep 1;25(17):5315-5328
pubmed: 31182433
Cancer Immunol Immunother. 2014 Oct;63(10):1073-80
pubmed: 24756420
J Neurosurg. 2012 Aug;117(2):227-33
pubmed: 22702482
J Clin Invest. 2016 Sep 1;126(9):3447-52
pubmed: 27525433
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Cancer. 2002 Apr 15;94(8):2265-72
pubmed: 12001126
Oncotarget. 2017 Jan 31;8(5):8738-8751
pubmed: 28060732